leisure time -WSS

leisure time

author：comprehensive 2025-09-03 03:33:18 - browse：599

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： What PEPFAR has meant on the ground in Ukraine

WSS

The world needs the new pandemic treaty

Louisiana bill approved classifying abortion pills as controlled substances

What causes an itch? Researchers may have solved the mystery

The woman behind the Dana Farber

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Protect nursing home residents from future pandemics

hotspot

leisure time

focus

Hollywood unions extend contract negotiations for actors

Roche to buy Carmot Therapeutics, developer of obesity drugs

Affirmative action in medical school literally saved lives

New research sheds light on how often breast cancer is overdiagnosed

Medicare proposal to cover medical devices draws a mixed reaction

After sickle

Psychedelics group wrestles with new pharma identity

The Bio Revolution is changing business and society

Anesthesiologist group: stop taking Ozempic before surgery

Congenital heart disease patients face new threat of heart failure

explore

SCOTUS to consider access to abortion pill mifepristone

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

U.S. death rates show how politics are affecting public health

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

FDA needs staff influx to meet gene therapy needs, Marks says

entertainment

focus

focus

knowledge